Delving into the Latest Updates on Valdepharm with Synapse

Overview

Tags

Digestive System Disorders

Neoplasms

Small molecule drug

Contrast agent

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Small molecule drug	1
Contrast agent	1

主要目的：评价研究者选择的单独放疗（RT）或联合西妥昔单抗的放疗激活瘤内注射NBTXR3在受试者中的生存结局（以下简称NBTXR3/RT±西妥昔单抗与RT±西妥昔单抗）。次要目的：关键次要目的是评价NBTXR3/RT±西妥昔单抗与RT±西妥昔单抗的长期生存结局。

[Translation]

Primary objective: To evaluate the survival outcomes of subjects receiving radiotherapy (RT) alone or in combination with cetuximab (hereinafter referred to as NBTXR3/RT±cetuximab vs. RT±cetuximab) in subjects selected by the investigator (hereinafter referred to as NBTXR3/RT±cetuximab vs. RT±cetuximab). Secondary objective: The key secondary objective is to evaluate the long-term survival outcomes of NBTXR3/RT±cetuximab vs. RT±cetuximab.

Start Date15 Jul 2022

Sponsor / Collaborator

Nanobiotix SA

[+2]

100 Clinical Results associated with Valdepharm

Login to view more data

0 Patents (Medical) associated with Valdepharm

Login to view more data

100 Deals associated with Valdepharm

Login to view more data

100 Translational Medicine associated with Valdepharm

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 3 Clinical

1

Login to view more data